Phase_I/II_trial_of_recombinant_human_granulocyte-macrophage_colony-stimulating_factor_following_allogeneic_bone_marrow_transplantation._Forty-seven_patients_with_hematologic_neoplasia_received_recombinant_human_granulocyte-macrophage_colony-stimulating_factor_(rhGM-CSF)_by_daily_2-hour_infusion_following_allogeneic_bone_marrow_transplantation_from_HLA-identical_sibling_donors_in_a_phase_I-II_dose-escalation_trial._Dose_levels_ranged_from_30_to_500_micrograms/m2/d._At_doses_at_or_below_250_micrograms/m2/d,_toxicity_felt_to_be_caused_by_rhGM-CSF_was_negligible._However,_three_of_five_patients_treated_with_500_micrograms/m2/d_had_unacceptable_side_effects_caused_by_rhGM-CSF._Two_different_graft-versus-host_disease_(GVHD)_prophylactic_regimens_were_administered._Twenty-seven_evaluable_patients_were_administered_regimens_that_did_not_contain_methotrexate_(MTX)_(Group_I)_and_reached_an_absolute_neutrophil_count_of_1,000/microL_by_a_median_of_day_14._In_contrast,_18_patients_who_received_GVHD_prophylactic_regimens_containing_MTX_(Group_II)_reached_an_absolute_neutrophil_count_of_1,000/microL_on_a_median_of_day_20._Patients_in_Group_I_had_fewer_febrile_days_and,_of_those_discharged,_had_shorter_initial_hospitalizations_than_patients_in_Group_II._The_overall_incidence_of_severe_acute_GVHD_(grade_2_or_greater)_in_the_rhGM-CSF-treated_patients_was_28%_and_was_similar_to_that_in_historical_"good_risk"_patients_who_did_not_receive_rhGM-CSF._These_preliminary_data_suggest_rhGM-CSF_is_unlikely_to_exacerbate_GVHD_in_HLA-identical_sibling_donor_transplants_and_indicate_the_need_for_randomized_trials_of_rhGM-CSF_in_allogeneic_marrow_transplant_patients.